Abstract:PURPOSE:Cisplatin can cause a variety of DNA crosslink lesions including intra-strand and inter-strand crosslinks (ICLs), which are associated with the sensitivity of cancer cells to cisplatin. Here, we aimed to assess the contribution of the Fanconi anemia (FA), homologous recombination (HR) and nucleotide excision repair (NER) pathways to cisplatin resistance in non-small cell lung cancer (NSCLC)-derived cells.METHODS:The expression of FA, HR and NER pathway-associated genes was assessed by RT-qPCR and Western blotting. siRNAs were used to knock down the expression of these genes. CCK-8 and flow cytometry assays were used to assess the viability and apoptotic rate of NSCLC-derived cells, respectively. Immunofluorescence and alkaline comet assays were used to assess the repair of ICLs.RESULTS:We found that acquired cisplatin-resistant NSCLC-derived A549/DR cells exhibited markedly enhanced FA and HR repair pathway capacities compared to its parental A549 cells and another independent NSCLC-derived cell line, Calu-1, which possesses a moderate innate resistance to cisplatin. siRNA-mediated silencing of the FA-associated genes FANCL and RAD18 and the HR-associated genes BRCA1 and BRCA2 significantly potentiated the sensitivity of A549/DR cells to cisplatin compared to A549 and Calu-1 cells, suggesting that the acquired cisplatin resistance in A549/DR cells may be attributed to enhanced FA and HR pathway capacities responsible for ICL repair. Although we found that expression knockdown of the NER-associated genes XPA and ERCC1 sensitized the three NSCLC-derived cell lines to cisplatin, the sensitization effect was more significant in Calu-1 cells than in A549 and A549/DR cells, implying that the innate cisplatin resistance in Calu-1 cells may result from an increased NER activity.CONCLUSIONS:Our results indicate that the functional status of DNA repair pathways determine the sensitivity of NSCLC cells to cisplatin. Direct targeting of the pathway that is involved in cisplatin resistance may be an effective strategy to surmount cisplatin resistance in NSCLC.

Notch1 Inhibition Enhances DNA Damage Induced by Cisplatin in Cervical Cancer

Notch1 Promotes Resistance to Cisplatin by Up-Regulating Ecto-5′-nucleotidase (CD73) in Triple-Negative Breast Cancer Cells

Advances of NOTCH 1 Signaling in Cervical Cancer

Targeting Notch1 signaling pathway positively affects the sensitivity of osteosarcoma to cisplatin by regulating the expression and/or activity of Caspase family

Correlation of Notch1 Expression and Activation to Cisplatin-Sensitivity of Head and Neck Squamous Cell Carcinoma.

Cisplatin treatment leads to changes in nuclear protein and microRNA expression

NOTCH1 Inhibition Enhances the Efficacy of Conventional Chemotherapeutic Agents by Targeting Head Neck Cancer Stem Cell

Expression of Stat3 and Notch1 is Associated with Cisplatin Resistance in Head and Neck Squamous Cell Carcinoma.

The Interaction Between PDCD4 and YB1 is Critical for Cervical Cancer Stemness and Cisplatin Resistance.

Antisense oligodeoxynucleotide targeting chk1 increases sensitivity of HeLa cells to apoptosis induced by DDP

The Role of Notch1 Genes in Lung Cancer A594 Cells and the Impact on Chemosensitivity

Cisplatin Inhibits Proliferation of Cervical Carcinoma Cell Line by Up-Regulating Stat1 Expression

RETRACTED: Inhibition of Notch1 Reverses EMT and Chemoresistance to Cisplatin Via Direct Downregulation of MCAM in Triple‐negative Breast Cancer Cells

Γ-Secretase Inhibition Combined with Cisplatin Enhances Apoptosis of Nasopharyngeal Carcinoma Cells

CHD1L Contributes to Cisplatin Resistance by Upregulating the ABCB1-NF-κB Axis in Human Non-Small-cell Lung Cancer.

Inhibition of Notch1 reverses EMT and chemoresistance to cisplatin via direct downregulation of MCAM in triple‐negative breast cancer cells

Inhibition of the PIN1-NRF2/GPX4 axis imparts sensitivity to cisplatin in cervical cancer cells

The Functional Status of DNA Repair Pathways Determines the Sensitization Effect to Cisplatin in Non-Small Cell Lung Cancer Cells.

Enhanced Cisplatin Cytotoxicity by RNA Interfering the Excision Repair Cross-complementing Gene 1 in Lung Cancer Cell A549/DDP

Cisplatin selects for stem-like cells in osteosarcoma by activating notch signaling.

Inhibition of the notch signaling pathway overcomes resistance of cervical cancer cells to paclitaxel through retardation of the epithelial–mesenchymal transition process